

An Amazing Sequence Arrangement.....

In 1976, the first isolated fragments of mammalian mRNA just didn't match the genes. Then in 1977....



'This startling fact [splicing] has abruptly changed our conception of what a eukaryotic gene is and how its expression is controlled' Broker & Chow

Genome size and organism complexity



• Exons and introns

The most common pattern studied is for a gene with 2 exons and one intron

But the mean gene: is 28,000 base pairs and 7 exons amounting to 2,400 bp

The gene encoding dystrophin is 2,400,000 bp long, contains 79 exons, and takes 16 hr to transcribe.



- Essential step in gene expression
- >15-50% of human genetic diseases involve splicing errors

Alternative splicing

• Important *regulatory* step in gene expression

(a) Retained intron



(b) Competing 5' splice sites



(c) Competing 3' splice sites



(d) Multiple promoters



(e) Multiple poly(A) sites



(f) Cassette exons



(g) Mutually exclusive exons



Current Opinion in Chemical Biology

- Regulation of gene expression increase the complexity by increasing the combinatorial use of exons by alternative splicing



RNA splicing gets the most out of genes

In animals, complexity depends less upon the number of genes than upon the number of different ways they can splice the RNA

So even if you found an exon, you couldn't tell how or when it might be used. Splicing exhibits extraordinary fidelity but selective promiscuity

Alternative splicing: functional consequences

Protein - Substitution/deletion of domains, change of reading frame, termination of reading frame

- Altered localization
- Antagonistic isoforms
- Modulation of function
- Unrelated proteins
- On/off switch for gene expression

Developmental -

- Sex determination in Drosophila
- Apoptosis

Pathology - misregulation of alternative splicing and disease.

•Cystic fibrosis

•Myotonic Dystrophy, Spinal Muscular Atrophy

- •FTDP1 Fronto-temporal dementia
- •WT-1 Wilms tumors

Drosophila Dscam encodes 38,016 distinct axon guidance receptors through the mutually exclusive alternative splicing of 95 variable exons.



Organization of the *D. melanogaster Dscam* gene. *Dscam* contains 115 exons, 95 of which are alternatively spliced. The exon 4, 6, and 9 clusters contain 12, 48, and 33 alternative exons, respectively, that each encode variable immunoglobulin domains. The exon 17 cluster contains two exons that encode alternate versions of the transmembrane domain. The exons within each cluster are alternatively spliced in a mutually exclusive manner. The exon 6 cluster is enlarged to depict its organization.

• Recognition of canonical splice sites





10-15% of single nucleotide mutations causing disease affect splice sites

From: H. Stark, P. Dube, R. Luhrmann & B. Kastner, Nature 409, 539 - 542 (2001)

• Mutations at constitutive splice sites: exon skipping





Mechanistic models connecting ESEs and SRs



Both enhancer (ESE) and silencer (ESS) of splicing exist. They activate or repress splicing on the neibouring splce sites



Nature Reviews | Genetics

Both enhancer (ESE) and silencer (ESS) of splicing exist. They activate or repress splicing on the neibouring splce sites

An example of silencers are the HnRNPs (heterogeneous ribonuclear proteins) which bind RNA but do not recruit the splicing machinery due to the lack of the SR domain



How splice sites are recognized in alternative splicing?

SR proteins bind inside exons on enhancer sites (ESE) and recruit the splicing apparatus on the 5' and 3' splice sites

SR proteins have a RNA binding domain and a arginine (R)-serine (S)-rich domain responsible for recruitment of the splicing apparatus



Regulatory elements in pre-mRNA splicing



Cis acting regulatory elements

- ESE Exonic Splicing Enhancer
- ESS Exonic Splicing Silencer
- ISS Intronic Splicing Enhancer
- ISE Intronic Splicing Silencer
- CERES Composite Exonic Regulatory Elements of Splicing

Trans-acting factors

| SR proteins | Serine arginine rich proteins (SF2/ASF) |
|-------------|---|
| hnRNPs | heterogeneous nuclear RiboNucleoprotein Particles (hnRNPA1) |
| snRNPs | small nuclear RiboNucleoProteins (U1 snRNP, U2 snRNP) |

Mutations in sequences involved in the splicing reaction may cause disease onset

Es. one silent mutation in the ESE of the BRCA1 gene, which predispose to breast cancer, induces exon skipping.

Es. some mutations in the B-globin gene produce slpicing alterations in thalassemic patients



Nat Genet. 2003

•A considerable number of disease causing mutations in exons or introns may disrupt previously unrecognised splicing regulatory elements

•Variability in the basal splicing machinery among different cell types cause cell-specific sensitivities to individual splicing mutations

•Exon sequence variation at CERES elements may represent a frequent disease-causing mechanism

•Even the most benign looking polymorphism in an exon (or in an intron) cannot be ignored as it may affect the splicing process

Single point mutations in coding exons



-

++

Silent mutations



Pagani et al Hum Mol Genet 2003

Exon mutations associated with disease

| 0 | b.f | Fran | 0 | B d | |
|---------------|----------|------|--------------|--------------------|--|
| Gene | Mutation | Exon | Gene | Mutation | |
| Missense muta | | _ | PDHA1 | A175T | |
| ADA | A215T | 7 | PMM2 | E139K | |
| ATM | E2032K | 44 | RHAG | G380V | |
| ATP7A | G1302R | 4 | | | |
| BRCA1 | E1694K | 18 | | | |
| CFTR | G58E | 9 | Silent mutat | ions | |
| | D565G | 12 | APC | R623R | |
| F8 | R1997W | 19 | AR | S888S | |
| FAH | Q279R* | 9 | ATM | S706S‡ | |
| FBN2 | D1114H‡ | 25 | | S1135S‡ | |
| FECH | A155P# | 4 | CYP27A1 | G112G | |
| HEXB | P404L | 11 | FAH | N232N | |
| IMBS | E29L‡ | 3 | FBN1 | 121181 | |
| HPRT1 | G40V | 2 | HEXA | L187L‡ | |
| | R48H | 3 | HMBS | R28R | |
| | A161E | 6 | HPRT1 | F199F | |
| | G180E | 8 | /TGB3 | T420T | |
| | G180V | 8 | LIPA | Q277Q‡ | |
| | E182K | 8 | MAPT | L284L§ | |
| | P184L | 8 | | N296N [§] | |
| | D194Y | 8 | | S305S‡§ | |
| | E197K | 8 | MLH1 | S577S‡ | |
| | E197V | 8 | NF1 | K354K | |
| | D201V | 8 | PAH | V399V | |
| IL2RG | R285Q‡ | 6 | PDHA1 | G185G‡ | |
| IVD | R21C | 2 | PKLR | A423A | |
| | R21P | 2 | PTPRC | P48P | |
| | D20N | 2 | PTS | E81E [‡] | |
| MAPT | N279K§ | 10 | RET | 16471 | |
| | S305N*§ | 10 | SMN1 | F280F | |
| MLH1 | R659P | 17 | TNFRSF5 | T136T | |
| | | 11 | 1797 7 107 0 | 11001 | |



Cartegni et al. (2002). Nature Reviews Genetics 3, 285-298.

Splicing modulators: the SR proteins



| 3. Human SR Related Proteins | | | | |
|------------------------------|---------------|--|--|--|
| U2 Auxiliary Factor | | | | |
| U2AF35 | | | | |
| U2AF65 | | | | |
| snRNP Components | | | | |
| U1-70K | | | | |
| U5-100K | RS DEXD/H Box | | | |
| U4/U6•U5-27K | RS | | | |
| hLuc7p | Zn Zn RS | | | |
| Splicing Regulators | | | | |
| hTra2α | RS RRM RS | | | |
| hTra2β | RS RRM RS | | | |
| Splicing Coactivators | | | | |
| SRm160 | RS | | | |
| SRm300 | | | | |
| RNA Helicases | | | | |
| hPrp16 | RS DEXD/H Box | | | |
| HRH1 | RS DEXD/H Box | | | |
| Protein Kinases | | | | |
| Clk/Sty | RS Kinase | | | |

FIGURE 2. Schematic diagram of human SR proteins and SR related proteins. A: The domain structures of the known members of the human SR protein family are depicted. RRM: RNA recognition motif; RRMH: RRM homology; Z: zinc knuckle, RS: arginine/ serine-rich domain. B: The domain structures for some of the human SRrps that participate in pre-mRNA splicing are depicted. All proteins, with the exception of SRm300, are drawn to scale. RRM: RNA recognition motif; RS: arginine/serine-rich domain; Zn: zinc finger; DEXD/H Box: motif characteristic of RNA helicases.

Challenges for the future

The basic distinction between exons and introns might be laid down by such proteins long before the specific splicing components bind.

There are over 50 proteins that are not part of the splicing complexes but bind to the RNA independently and affect the choice of sites.

The **BRCA1 gene**, located on chromosome band 17q21, has a coding sequence of 5,592 nucleotides scattered on 22 exons. However, <u>the exact function of the gene is still unclear</u>, although the encoded proteins are involved in various cellular processes, including transcriptional regulation and DNA repair pathways. Germ-line mutations in this gene lead to the predisposition to breast and ovarian cancer. More than 1,250 different mutations of the *BRCA1* gene have been reported worldwide, spread over the entire length of the gene; most of them lead to premature-termination codons, as a result of frameshift, nonsense, or splice-site mutations or large rearrangements

The power of point mutations L E Maquat Nature Genetics 27, 5 - 6 (2001).

Studies of human diseases have shown that nonsense mutations can alter premRNA splicing. A new study, focusing on the breast cancer susceptibility gene, *BRCA1*, demonstrates that one explanation lies in a disrupted exonic splicing enhancer rather than a disrupted translational reading frame. Despite the growing appreciation of the frequent occurrence of exonic sequences that affect the use of splice sites, the prevalence of single-nucleotide polymorphisms that alter splicing has probably been vastly underestimated.

Nat Genet. 2001, 1:55-8.

A mechanism for exon skipping caused by nonsense or missense mutations in *BRCA1* and other genes

Hong-Xiang Liu1, 2, Luca Cartegni1, Michael Q. Zhang1 & Adrian R. Krainer1

Point mutations can generate defective and sometimes harmful proteins. The nonsense-mediated mRNA decay (NMD) pathway minimizes the potential damage caused by nonsense mutations. In-frame nonsense codons located at a minimum distance upstream of the last exon-exon junction are recognized as premature termination codons (PTCs), targeting the mRNA for degradation. Some nonsense mutations cause skipping of one or more exons; this phenomenon is termed nonsensemediated altered splicing (NAS). By analyzing NAS in BRCA1, we show here that inappropriate exon skipping can be reproduced in vitro, and results from disruption of a splicing enhancer in the coding sequence. Enhancers can be disrupted by single nonsense, missense and translationally silent point mutations, without recognition of an open reading frame as such. These results argue against a nuclear reading-frame scanning mechanism for NAS. Coding-region single-nucleotide polymorphisms (cSNPs) within exonic splicing enhancers or silencers may affect the patterns or efficiency of mRNA splicing, which may in turn cause phenotypic variability and variable penetrance of mutations elsewhere in a gene.



Figure 1: High-score SR protein motifs in BRCA1 exon 18.

We searched the 78-nt sequence of wild-type exon 18 with four nucleotidefrequency matrices derived from pools of functional enhancer sequences selected *in vitro*. Motif scores reflect the extent of matching to a degenerate consensus, and only the scores above the threshold for each SR protein are shown. Highscore motifs are shown in black for SF2/ASF, dark gray for SC35, light gray for SRp40 and white for SRp55. The width of each bar reflects the length of the motif (6, 7 or 8 nt); the placement of each bar along the x axis, the position of a motif along the wild-type exon DNA sequence; and the height of the bar, the numerical score on the y axis. The thresholds and maximal values are different for each SR protein. The G at position 6 (wild type) is highlighted. The nonsense mutation that changes this G to a T only affects the first SF2/ASF motif, reducing the score from 2.143 to 0.079 (below the threshold).



In vitro splicing of *BRCA1* minigene transcripts reproduces the exon-skipping phenotype of a nonsense mutation.

We generated wild-type and mutant BRCA1 **minigene** transcripts by PCR and in vitro transcription. We deleted an internal portion of each intron—away from the splice sites and branch site—to generate pre-mRNAs of adequate length for *in vitro* splicing. We spliced wild-type (WT, lane 1) and nonsense mutant with low SF2/ASF score (NL, lane 2) radiolabeled transcripts in HeLa cell nuclear extract, and analyzed the products of the reaction by denaturing PAGE and autoradiography. The identity of each band is indicated schematically on the right. Exons 17 and 19 are shown as gray boxes, exon 18 as a white box, and the shortened introns as lines. The arrows indicate the mRNAs generated by exon 18 inclusion or skipping. Although the extent of exon inclusion and skipping varied with different extract preparations or buffer conditions, the ratio of exon skipping over inclusion was reproducibly greater with the mutant premRNA